These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16677415)

  • 1. Cancer and kinases: reports from the front line.
    Burley SK
    Genome Biol; 2006; 7(4):314. PubMed ID: 16677415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary: Novel therapies for cancer: why dirty might be better.
    Fojo T
    Oncologist; 2008 Mar; 13(3):277-83. PubMed ID: 18378537
    [No Abstract]   [Full Text] [Related]  

  • 3. Resensitizing Refractory ALK+ NSCLC: A Case Study.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):220-1. PubMed ID: 26801737
    [No Abstract]   [Full Text] [Related]  

  • 4. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies.
    Hu-Lowe D; Brega N; Patyna S
    Mol Cancer Ther; 2011 Nov; 10(11):2015. PubMed ID: 22072801
    [No Abstract]   [Full Text] [Related]  

  • 5. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule inhibitors of protein kinases in cancer- how to overcome resistance.
    Griffith R; Brown MN; McCluskey A; Ashman LK
    Mini Rev Med Chem; 2006 Oct; 6(10):1101-10. PubMed ID: 17073710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
    Wardak Z; Choy H
    J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
    [No Abstract]   [Full Text] [Related]  

  • 11. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumour-agnostic drugs and future cancer treatment.
    Børset M
    Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872821
    [No Abstract]   [Full Text] [Related]  

  • 13. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase inhibitors.
    Crescenzo R; Inghirami G
    Curr Opin Pharmacol; 2015 Aug; 23():39-44. PubMed ID: 26051994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P
    Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.
    Thirumal Raj A; Patil S; Ranadheer R; Chandini R
    Oral Oncol; 2017 Oct; 73():172. PubMed ID: 28923250
    [No Abstract]   [Full Text] [Related]  

  • 19. Bad patients meet good drugs.
    Lacal JC
    Clin Transl Oncol; 2006 Apr; 8(4):225-7. PubMed ID: 16648096
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted therapy for solid tumors: current status.
    Zureikat AH; McKee MD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.